Hepatocellular carcinoma (HCC) is an aggressive malignancy, resulting as the third cause
of death by cancer each year. The management of patients with HCC is complex, as both the …

Background. Hepatocellular carcinoma is one of the most common and lethal malignant
tumors worldwide. Over the past 15 years, the incidence of HCC has more than doubled …

Since then, several first-line clinical trials have been conducted with the aim of developing
molecular targeted agents showing better efficacy or safety than sorafenib [3](Table 1). A …

Objectives To assess the inter-operator concordance and the potential sources of
discordance in defining response to sorafenib in hepatocellular carcinoma (HCC). Methods …

Simple Summary Skeletal muscle depletion is one of the established prognostic factors for
hepatocellular carcinoma (HCC). This study clearly demonstrated that skeletal muscle mass …

Abstract Background & Aims Response Evaluation Criteria in Solid Tumors (RECIST) has
been shown to be a poor surrogate for survival benefit with targeted therapy in advanced …

The aim of this study was to investigate whether rapid depletions of fat mass and skeletal
muscle mass predict mortality in hepatocellular carcinoma (HCC) patients treated with …

The aim of this study was to determine whether skeletal muscle depletion predicts the
prognosis of patients with hepatocellular carcinoma (HCC) that is being treated with …

Advanced stage hepatocellular carcinoma (HCC) is a category of disease defined by
radiological, clinical and hepatic function parameters, comprehending a wide range of …

Abstract Response Evaluation Criteria in Solid Tumors (RECIST) is inappropriate to assess
the direct effects of treatment on hepatocellular carcinoma (HCC) by locoregional therapies …